Literature DB >> 20164263

Crimean-Congo hemorrhagic fever virus infection is lethal for adult type I interferon receptor-knockout mice.

Sándor Bereczky1, Gunnel Lindegren, Helen Karlberg, Sara Akerström, Jonas Klingström, Ali Mirazimi.   

Abstract

Crimean-Congo hemorrhagic fever virus (CCHFV) poses a great threat to public health due to its high mortality, transmission and geographical distribution. To date, there is no vaccine or specific treatment available and the knowledge regarding its pathogenesis is highly limited. Using a small-animal model system, this study showed that adult mice missing the type I interferon (IFN) receptor (IFNAR(-/-)) were susceptible to CCHFV and developed an acute disease with fatal outcome. In contrast, infection of wild-type mice (129 Sv/Ew) was asymptomatic. Viral RNA was found in all analysed organs of the infected mice, but the amount of CCHFV RNA was significantly higher in the IFNAR(-/-) mice than in the wild-type mice. Furthermore, the liver of IFNAR(-/-) mice was enlarged significantly, showing that IFN is important for limiting virus spread and protecting against liver damage in mice.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20164263     DOI: 10.1099/vir.0.019034-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  69 in total

Review 1.  The use of mice lacking type I or both type I and type II interferon responses in research on hemorrhagic fever viruses. Part 2: Vaccine efficacy studies.

Authors:  Marko Zivcec; Christina F Spiropoulou; Jessica R Spengler
Journal:  Antiviral Res       Date:  2020-01-22       Impact factor: 5.970

Review 2.  Recent advances in research on Crimean-Congo hemorrhagic fever.

Authors:  Anna Papa; Ali Mirazimi; Iftihar Köksal; Augustin Estrada-Pena; Heinz Feldmann
Journal:  J Clin Virol       Date:  2014-10-22       Impact factor: 3.168

Review 3.  Hemorrhagic fever of bunyavirus etiology: disease models and progress towards new therapies.

Authors:  Brian B Gowen; Brady T Hickerson
Journal:  J Microbiol       Date:  2017-02-28       Impact factor: 3.422

4.  A virus-like particle system identifies the endonuclease domain of Crimean-Congo hemorrhagic fever virus.

Authors:  Stephanie Devignot; Eric Bergeron; Stuart Nichol; Ali Mirazimi; Friedemann Weber
Journal:  J Virol       Date:  2015-03-25       Impact factor: 5.103

5.  Exploring Crimean-Congo Hemorrhagic Fever Virus-Induced Hepatic Injury Using Antibody-Mediated Type I Interferon Blockade in Mice.

Authors:  Michael E Lindquist; Xiankun Zeng; Louis A Altamura; Sharon P Daye; Korey L Delp; Candace Blancett; Kayla M Coffin; Jeffrey W Koehler; Susan Coyne; Charles J Shoemaker; Aura R Garrison; Joseph W Golden
Journal:  J Virol       Date:  2018-10-12       Impact factor: 5.103

Review 6.  Animal Models of Zika Virus.

Authors:  Michael P Bradley; Claude M Nagamine
Journal:  Comp Med       Date:  2017-06-01       Impact factor: 0.982

7.  Pathogenesis and immune response of Crimean-Congo hemorrhagic fever virus in a STAT-1 knockout mouse model.

Authors:  Dennis A Bente; Judie B Alimonti; Wun-Ju Shieh; Gaëlle Camus; Ute Ströher; Sherif Zaki; Steven M Jones
Journal:  J Virol       Date:  2010-08-25       Impact factor: 5.103

8.  Lethal Crimean-Congo hemorrhagic fever virus infection in interferon α/β receptor knockout mice is associated with high viral loads, proinflammatory responses, and coagulopathy.

Authors:  Marko Zivcec; David Safronetz; Dana Scott; Shelly Robertson; Hideki Ebihara; Heinz Feldmann
Journal:  J Infect Dis       Date:  2013-02-15       Impact factor: 5.226

9.  Crimean-Congo Hemorrhagic Fever Virus Subunit Vaccines Induce High Levels of Neutralizing Antibodies But No Protection in STAT1 Knockout Mice.

Authors:  Jeroen Kortekaas; Rianka P M Vloet; Alexander J McAuley; Xiaoli Shen; Berend Jan Bosch; Laura de Vries; Rob J M Moormann; Dennis A Bente
Journal:  Vector Borne Zoonotic Dis       Date:  2015-12       Impact factor: 2.133

10.  Heterologous protection against Crimean-Congo hemorrhagic fever in mice after a single dose of replicon particle vaccine.

Authors:  Jessica R Spengler; Stephen R Welch; Florine E M Scholte; JoAnn D Coleman-McCray; Jessica R Harmon; Stuart T Nichol; Éric Bergeron; Christina F Spiropoulou
Journal:  Antiviral Res       Date:  2019-08-01       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.